Alterity Therapeutics Ltd: Phase 2 DMC Recommends Continuing Clinical Trial as Planned
Alterity Therapeutics Ltd: Quarterly Activities/Appendix 4C Cash Flow Report
Alterity Therapeutics Ltd: Alterity Presents New Data on ATH434
Alterity Therapeutics Ltd: Alterity Parkinson's and MSA Data Featured at AAN Meeting
Alterity Therapeutics Ltd: Alterity to Present New ATH434 Data at Orphan Drug Congress
Alterity Therapeutics Ltd: Alterity Receives a $3.9 million R&D Tax Incentive Refund
Alterity Therapeutics Ltd: Trading Halt
Alterity Therapeutics Ltd: Alterity to Present New Data at the AAN 2024 Annual Meeting
Alterity Therapeutics Ltd: Phase 2 DMC Recommends Continuing Clinical Trial as Planned
Alterity Therapeutics Ltd: Quarterly Activities/Appendix 4C Cash Flow Report
Alterity Therapeutics Ltd: Change of Director's Interest Notice PM BM
Alterity Therapeutics Ltd: Alterity Appoints Phillip Hains as Chief Financial Officer
Alterity Therapeutics Ltd: Grant of Waiver & Addendum - EGM 29 December 2023
Alterity Therapeutics Ltd: Virtual access to Extraordinary General Meeting 29 Dec 2023
Alterity Therapeutics Ltd: Webcast to Discuss ATH434 Efficacy Data in Primate Model
Alterity Therapeutics Ltd: Positive Efficacy Data for ATH434 in a Primate Model of PD
Alterity Therapeutics Ltd: Chairman's Address 2023 Annual General Meeting
Alterity Therapeutics Ltd: ATH presents Novel Biomarker Data for Evaluation of MSA
Alterity Therapeutics Ltd: Trading Halt
Alterity Therapeutics Ltd: New Data Demonstrating Novel Mechanisms of ATH434
No Data